CA2594676A1 - Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors - Google Patents

Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors Download PDF

Info

Publication number
CA2594676A1
CA2594676A1 CA002594676A CA2594676A CA2594676A1 CA 2594676 A1 CA2594676 A1 CA 2594676A1 CA 002594676 A CA002594676 A CA 002594676A CA 2594676 A CA2594676 A CA 2594676A CA 2594676 A1 CA2594676 A1 CA 2594676A1
Authority
CA
Canada
Prior art keywords
alkyl
chosen
substituted
alkoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002594676A
Other languages
English (en)
French (fr)
Inventor
Ruiping Liu
Mark Phillip Arrington
Allen Hopper
Ashok Tehim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2594676A1 publication Critical patent/CA2594676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002594676A 2004-12-23 2005-12-27 Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors Abandoned CA2594676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63817904P 2004-12-23 2004-12-23
US60/638,179 2004-12-23
PCT/US2005/047439 WO2006071988A1 (en) 2004-12-23 2005-12-27 Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors

Publications (1)

Publication Number Publication Date
CA2594676A1 true CA2594676A1 (en) 2006-07-06

Family

ID=36128394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002594676A Abandoned CA2594676A1 (en) 2004-12-23 2005-12-27 Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors

Country Status (7)

Country Link
US (2) US7576080B2 (enExample)
EP (1) EP1831229A1 (enExample)
JP (1) JP2008525500A (enExample)
AU (1) AU2005321903A1 (enExample)
CA (1) CA2594676A1 (enExample)
MX (1) MX2007007387A (enExample)
WO (1) WO2006071988A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754890C (en) 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
BR112012005616A2 (pt) * 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
KR101478889B1 (ko) * 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
WO2012044562A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
MX2014015345A (es) 2012-06-20 2015-03-05 Hoffmann La Roche Inhibidores piranopiridona de tanquirasa.
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CN105377192A (zh) 2013-05-09 2016-03-02 米塔埃瑟斯医疗有限公司 心脏瓣膜辅助修复体
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US11008339B2 (en) * 2015-05-18 2021-05-18 Shenyang Sinochem Agrochemicals R&D Co., Ltd. Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof
CN108358966B (zh) * 2018-03-05 2020-04-28 南京工业大学 一种靶向-增强线粒体功能药物Mito-VB3及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE3669315D1 (de) 1985-03-14 1990-04-12 Sankyo Co Phenoxyalkylaminopyrimidinderivate, deren herstellung und diese enthaltende insektizide und akarizide zusammensetzungen.
JPH02105081A (ja) 1988-10-14 1990-04-17 Mitsubishi Electric Corp アナログ試験装置
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
GB9517986D0 (en) 1995-09-04 1995-11-08 Sandoz Ltd Organic compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU7587996A (en) 1995-11-16 1997-06-05 Dnavec Research Inc. Process for constructing transgenic animals
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
ES2219033T3 (es) 1998-07-22 2004-11-16 Daiichi Suntory Pharma Co., Ltd. Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo.
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
EE200100502A (et) 1999-03-26 2002-12-16 Astrazeneca Ab Ühendid
JP4660045B2 (ja) 1999-09-17 2011-03-30 松森　　昭 ＮＦ−κＢ阻害剤を有効成分とする心筋炎、拡張型心筋症および心不全の予防または治療薬
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
US6945478B2 (en) * 2002-03-15 2005-09-20 Siemens Vdo Automotive Corporation Fuel injector having an orifice plate with offset coining angled orifices
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
KR101186678B1 (ko) 2003-06-11 2012-09-27 젠션 리미티드 포타슘 채널 억제제로서의 티에노피리미딘 유도체
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions

Also Published As

Publication number Publication date
JP2008525500A (ja) 2008-07-17
AU2005321903A1 (en) 2006-07-06
MX2007007387A (es) 2007-08-03
US20070259896A1 (en) 2007-11-08
US20100010017A1 (en) 2010-01-14
EP1831229A1 (en) 2007-09-12
US7576080B2 (en) 2009-08-18
WO2006071988A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US20100010017A1 (en) Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
US20070093515A1 (en) Phosphodiesterase 10 inhibitors
ES2334650T3 (es) Derivados de 4(4-alkoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos.
AU2011351375B2 (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US20060160814A1 (en) Phosphodiesterase 10 inhibitors
US11261164B2 (en) Small molecule agonists of neurotensin receptor 1
RS62874B1 (sr) Inhibitori lizin specifične demetilaze-1
AU2021269397B2 (en) Compounds and compositions for the treatment of cancer
RS63074B1 (sr) Inhibitori lizin specifične demetilaze-1
CA2753236A1 (en) Pyrrolopyrimidines used as kinase inhibitors
WO2023224998A1 (en) Inhibitors of parg
KR20080108540A (ko) 아미노메틸피리딘 유도체, 그의 제조 방법 및 그의 치료학적 용도
RS57532B1 (sr) Biciklično jedinjenje koje sadrži sumpor
AU2023271807A1 (en) Inhibitors of parg
CA2740406A1 (en) Methylene amines of thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
JP2007509123A (ja) キナーゼ阻害剤としてのチエノ−ピリジノン誘導体
CA2740408A1 (en) Amides of thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
US20100144714A1 (en) Derivatives of imidazo pyrimido and diazepine pyrimidine-dione, and use thereof as a drug
CA2740410A1 (en) Phenyl and heteroaryl substituted thieno[2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
EP4514806A1 (en) Compositions useful for modulating splicing
MX2011003967A (es) Tieno[2,3-d]pirimidina sustituida con heterociclilo y cicloalquilo y su uso como antagonistas del receptor de adenosina a2a.

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20111228